Objective: To compare the BTA statTM test (BTA stat), a new one-step immunochromatographic assay that can be performed in the urologist’s office or in the laboratory, to voided urine cytology and bladder wash cytology (cytology) in the diagnosis and monitoring of cancer of the bladder (BC). Methods: BTA stat and cytology were performed in a double-blinded, prospective, clinical study on specimens from 240 subjects (68 females; mean age of subjects: 64 years) suspected of having BC. Results: In 107 subjects with final diagnoses of BC confirmed by cystoscopy or cystoscopy and biopsy, the overall sensitivities of BTA stat and cytology were 65 and 33%, respectively. For tumor grades I, II, and III, the sensitivities of BTA stat were 39, 67 and 83%, respectively. Those of cytology were 4, 20 and 69%. Nine subjects had a diagnosis of ‘suspicious for bladder cancer’. The specificities of BTA stat and cytology in the 124 subjects without BC were 64 and 99%, respectively. In the subjects with a history of BC (n = 74), the specificities of BTA stat and cytology were 72 and 99%, respectively. The specificity of BTA stat was lower in subjects with benign or malignant genitourinary disease other than BC (46%) than in subjects without genitourinary disease (71%). Conclusions: The BTA stat test is considerably more sensitive than cytology in the detection of BC and can replace cytology as an adjunct to cystoscopy in the diagnosis and follow-up of patients with BC. However, due to low specificity, BTA stat should not be used without first ruling out potential interferences such as infections, renal disease and cancer, or genitourinary trauma.

Keywords:
Bladder cancer, Bladder neoplasms, BTA statTM test, Cytology, Tumor-associated antigen
1.
Badalament RA, Hermansen DK, Kimmel M, Gay H, Herr HW, Fair WR, Whitmore WF, Melamed MR: The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma. Cancer 1987;60:1423–1427.
2.
Murphy WM: Current status of urinary cytology in the evaluation of bladder neoplasms. Hum Pathol 1990;21:886–896.
3.
Ozols RF: Management of bladder cancer. Curr Probl Cancer 1995;19:4–63.
4.
Wiener HG, Vooijs GP, van’t Hof-Grootenboer B: Accuracy of urinary cytology in the diagnosis of primary and recurrent bladder cancer. Acta Cytol 1993;37:163–169.
5.
Sarosdy MF, deVere White RW, Soloway MS, Sheinfeld J, Hudson MA, Schellhammer PF, Jarowenko MV, Adams G, Blumenstein BA: Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J Urol 1995;154:379–384.
6.
d’Hallewin M-A, Baert L: Initial evaluation of the bladder tumor antigen test in superficial bladder cancer. J Urol 1995;155:475–476.
7.
Leyh H, Hall R, Mazemann E, Blumenstein BA: Comparison of the Bard® BTA® test with voided urine and bladder wash cytology in the diagnosis and management of cancer of the bladder. Urology 1997;50:49–53.
8.
Sarosdy MF, Hudson MA, Ellis WJ, Soloway MS, deVere White R, Sheinfeld J, Jarowenko MV, Schellhammer PF, Schervish EW, Patel JV, Chodak GW, Lamm DL, Johnson RD, Henderson M, Adams G, Blumenstein BA, Thoelke KR, Pfalzgraf RD, Murchison HA, Brunelle SL: Improved detection of recurrent bladder cancer using the BTA statTM Test. Urology 1997;50:349–353.
9.
Kinders R, Jones T, Root R, Murchison H, Bruce C, Williams L, Hass GM: Human bladder tumor antigen is a member of the RCA (regulators of complement activation) gene family. J Urol 1997;157(suppl):28.
10.
Kinders R, Root R, Jones T, Bruce CL, Hass GM: Complement factor H-related proteins are expressed in bladder cancers. Cancer Res AACR: Proceedings of the 88th Annual Meeting, San Diego, Calif., USA, 1997, vol 38, p 29, abstract No 189.
11.
Hermanek P, Sobin LH: UICC-International Union Against Cancer TNM classification of malignant tumours, ed 4. Heidelberg, Springer, 1987.
12.
Schork MA, Williams GW: Number of observations required for the comparison of two correlated proportions. University of Michigan Department of Biostatistics, Technical Report Series No. 9, 1976.
13.
Fradet Y, Cordon-Cardo C: Critical appraisal of tumor markers in bladder cancer. Semin Urol 1993;11:145–153.
14.
Rozanski TA, Grossman HB: Recent developments in the pathophysiology of bladder cancer. AJR 1994;163:789–792.
15.
Lokeshwar VB, Öbek C, Soloway MS, Block NL: Tumor-associated hyaluronic acid: A new sensitive and specific urine marker for bladder cancer. Cancer Res 1997;57:773–777.
16.
Olumi AF, Skinner EC, Tsai YC, Jones PA: Molecular analysis of human bladder cancer. Semin Urol 1990;8:270–277.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.